Shots:  

• The US FDA has granted ODD and FT destination to Elezanumab- which is an investigational treatment for patients following spinal cord injury
• The company is collaborating with Shirley Ryan AbilityLab and MC10 to evaluate elezanumab in a pilot study in 20 spinal cord injury patients. The pilot study will inform the ongoing P-II study of therapy by testing optimal biosensor placement to capture sEMG- among other assessments- and is expected to be completed in ~2mos.
• Elezanumab is a mAb of IgG1 isotype that binds selectively to RGMa- acts by inhibiting neuronal regeneration and functional recovery following CNS damage- currently being investigated spinal cord injuries- MS and AIS

­ Ref: AbbVie | Image: abbvie